Lonza Group AG
LONN
Rankning i aktier
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aktiekurs
$764.04
Marknadsvärde
$53.36B
Förändring (1 dag)
0.96%
Förändring (1 år)
8.59%
Land
CH
Handel Lonza Group AG (LONN)
Kategori
Healthcare
Historik för aktiesplit för Lonza Group AG (LONN)
Aktien Lonza Group AG (symbol: LONN) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 22, 2026.
En LONN-aktie köpt före Oct 22, 2026 motsvarar nu 0 LONN-aktier.
Den senaste spliten skedde den Oct 22, 2026.
En LONN-aktie köpt före Oct 22, 2026 motsvarar nu 0 LONN-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 1 | x100 |
BE
|
